Sato, Akira
Matsubayashi, Keisuke
Morishima, Toshitaka
Nakata, Kayo
Kawakami, Koji
Miyashiro, Isao
Funding for this research was provided by:
Osaka Health and Medical Foundation
the Osaka Foundation for the Prevention of Cancer and Lifestyle-related Diseases
Ministry of Health, Labour and Welfare, Japan (H30-Gantaisaku-Ippan-009)
Article History
Received: 7 July 2020
Accepted: 4 March 2021
First Online: 10 March 2021
Declarations
:
: This study was approved by the Research Ethics Committee of Osaka International Cancer Institute (Approval No. 18–0020; December 6, 2018) and the Kyoto University Graduate School of Medicine Ethics Committee (Approval No. R1808; December 18, 2018). The ethics committees waived the need for informed consent from the OCR-registered patients as the data were anonymized before being received by the authors. Osaka Cancer Registry data were accessed with permission from the Osaka Prefectural Government. The study was performed in accordance with the ethical standards outlined in the Declaration of Helsinki.
: Not applicable.
: KK has received research funds from Stella Pharma Corporation. The sponsor had no control over the interpretation, writing, or publication of this work. No potential conflicts of interest were disclosed by the other authors.